Devastating central nervous system injuries and diseases continue to occur in spite of the tremendous efforts of various prevention programs. The enormity of and annual escalation of healthcare costs due to them require that therapeutic strategies be responsibly developed. The dysfunctions that occur after injury and disease are primarily due to neurotransmission damage. The last two decades of both experimental and clinical research have demonstrated that neural and non-neural tissue and cell transplantation is a viable option for ameliorating dysfunctions to markedly improve quality of life. Moreover, significant progress has been made with tissue and cell transplantation in studies of pathophysiology, plasticity, sprouting, regeneration, and functional recovery. This chapter will review information about the ability and potential, particularly for traumatic spinal cord injury, that neural and non-neural tissue and cell transplantation has to replace lost neurons and glia, reconstruct damaged neural circuitry, and to restore neurotransmitters, hormones, neurotrophic factors, and neurotransmission. Donor tissues and cells to be discussed include peripheral nerve, fetal spinal cord and brain, central and peripheral nervous systems' glia, stem cells, those that have been genetically engineered, and non-neural ones. Combinatorial approaches and clinical research are also reviewed.
Introduction
Over the last two decades, neural and non-neural tissue and cell transplantation have been used extensively to study mechanisms of central nervous system (CNS) injury, plasticity, sprouting, regeneration, and recovery of function. The availability of potential donor tissues and cells (Table 1) for transplantation and the methods developed to obtain them now provide opportunity and flexibility for strategies to treat human CNS injuries and diseases. A transplant of neural tissue and cells may replace particular populations of neurons lost by injury and restore levels of neurotransmitters, hormones, neurotrophic factors, or neural circuitry. These transplants may also provide a population of neurons at the injury site which may serve as a relay to convey sensory and/or motor control to levels proximal and/or distal to the injury. Finally, neural and non-neural tissue and cell transplants, alone or in combination with other strategies, may serve as a bridge that supports axonal growth across the injury site to reach targets proximal and/or distal to the lesion. This chapter will briefly review the general principle and current advances of transplantation-mediated axonal regeneration with emphasis being placed on the advantages and disadvantages of using different neural and non-neural tissues and cell types, combinatorial approaches, as well as gene therapy in the repair of CNS injuries, particularly that of the spinal cord. For further information about some of the combinatorial approaches, the reader is referred to the chapters about neurotrophins, biomaterials, electrical stimulation, and physical activity. The reader is also referred to the chapter about clinical trials of therapies for spinal cord injury (SCI).
Tissue transplantation

Peripheral nerve
In contrast to the CNS, regeneration of axons in the adult mammalian peripheral nervous system (PNS) has long been known to occur and to result in varying extents of functional recovery. This information led Spanish investigators in the early 1900s to transplant pieces of peripheral nerve into areas of the CNS to assess the capacity of CNS axons to regenerate. When axonal growth into the transplants occurred, Ramón y Cajal and colleagues concluded that CNS axons had the capacity to regenerate if the environment is suitable, i.e. if appropriate "neutritive" and "orienting" substances are provided (Ramon y Cajal 1928) . This view did not flourish especially due to a number of equivocal results in experimental SCI reported in the 1940s and 1950s. In 1980, it was clearly shown with neuroanatomical tracing techniques that numerous axons of the spinal cord and dorsal root ganglion (DRG) neurons regrew into freshly dissected peripheral nerves acutely transplanted into a gap created in the adult rat spinal cord (Richardson et al. 1980) . Other papers documenting growth of axons from neurons in other parts of the CNS into peripheral nerve transplants followed. In fact, these nerve grafts enabled axons in some cases to regenerate to greater lengths than they had reached initially.
Advancements in using peripheral nerve transplantation for increasing injured CNS axon regeneration have been made during subsequent investigations. More DRG axons regenerated into acute transplants of freshly dissected and, even more so, pre-degenerated peripheral nerve when a conditioning peripheral nerve lesion occurred, that is, when the DRG peripheral axons were injured prior to or at the time of laceration SCI (Richardson et al. 1984) . Neurotrophins delivered to the spinal cord and brain, FK506, and knockdown of xylosyltransferase-1 mRNA acutely and chronically were seen to promote more growth of regenerated supraspinal (Ye et al. 1997) , spinal cord (Novikova et al. 2002) , and dorsal column (Oudega et al. 1996) axons into the spinal cord through peripheral nerve transplants. Chondroitinase ABC administration to the spinal cord to degrade inhibitory chondroitin sulfate proteoglycans also increased regenerated axon outgrowth from a peripheral nerve bypass transplant at a hemisection leading to robust functional recovery (Houle et al. 2006) .
Another advancement was the use of multiple peripheral nerve grafts across a transection and gap that redirect specific axon pathways from non-permissive white to permissive gray matter (Cheng et al. 1996) . Combined with the use of acidic fibroblast growth factor (aFGF, FGF1) and compressive wiring of posterior spinal processes, this study demonstrated certain degree of structural and functional recovery. This combination repair strategy was further confirmed by others (Lee et al. 2002) , was applied to chronic SCI (Fraidakis et al. 2004) , and was facilitated by overexpression of neurotrophin in the peripheral nerves (Blits et al. 2000) . The repair strategy was not effective in spinal cord injured non-human primates (Levi et al. 2002) . However, it was reported to improve motor and sensory function of a person with chronic SCI (Cheng et al. 2004) . Peripheral nerves also promoted axon regeneration and improved function when transplanted alone (Rasouli et al. 2006) or combined with neurotrophic factors (Sandrow et al. 2008) at the chronic contusive injury, a model of the frequent human SCI.
Martin and colleagues (Campos et al. 2004 ) developed an innovative way to promote regenerated axons bypassing a spinal lesion. In this study, they disconnected the T13 spinal nerve at its distal end and inserted it caudal to a L2/3 hemisection. Four to 28 weeks later, anterograde tracing indicated that axons from the inserted T13 spinal nerve regenerated into the spinal cord distal to the injury. In addition, electrical stimulation of the T13 spinal nerve evoked contraction of back and leg muscles, spasticity and muscle wasting was reduced, and mobility of multiple joints in the ipsilateral hindlimb was improved compared to lesion alone.
Importantly, central respiratory neurons regenerated axons into acute and chronic transplants of freshly dissected and pre-degenerated peripheral nerves into the medulla oblongata or cervical spinal cord respiratory pathways (Decherchi et al. 2002) . This led to phrenic nerve responses when the distal ends of the nerves were transplanted into the mid-cervical spinal cord to by-pass a rostral laceration injury (Decherchi et al. 2002) (Table 2) . It remains to be determined whether some of the additional approaches mentioned above, such as, administering neurotrophins and/or chondroitinase ABC into the spinal cord to enhance regenerated axon outgrowth from the transplants will be effective for central respiratory neurons. Additionally, whether peripheral nerve transplantation around or across the various types of cervical SCI is a rationale approach for repairing respiration is unknown. Lastly, the benefits and harms of performing autologous peripheral nerve transplants for repairing respiration needs to be further examined.
Fetal spinal cord or brain
Fetal tissue transplants have been used to repair the injured spinal cord by replacing lost neurons and supplying novel components of the spinal cord circuitry as well as by providing permissive conditions for axonal growth. Transplants of fetal spinal cord tissue into the motoneurondepleted or injured adult rat spinal cord survived and their axons grew through ventral root or peripheral nerve to innervate skeletal muscle and improve its function (Horvat 1991) . Fetal brainstem tissue transplants into cavities or transections also replaced lost supraspinal adrenergic and serotoninergic input of the adult rat spinal cord, enhanced the hindlimb flexion reflex, and activated locomotion (Ribotta et al. 2000) .
After spinal cord hemisection and transplantation of the fetal tissues as pieces alone or in suspension into the adult animals, host axons regenerated into the transplant but terminated near the host-transplant border (Jakeman et al. 1991; Bregman et al. 1997b) . Exogenous application of neurotrophic factors increases the intrinsic capacity of mature neurons for regrowth. For example, Bregman and colleagues showed that, after spinal cord hemisection and transplantation in the adult, exogenous administration of brain-derived neurotrophic factor (BDNF) or neurotrophin-3 (NT-3) increased supraspinal axonal growth within the transplant (Bregman et al. 1997b) , further prevented the atrophy of axotomized supraspinal neurons (Bregman et al. 1998) , and increased the expression of regeneration-associated genes within the cell bodies of the injured axons. They also reported that both the amount of axonal regrowth from both propriospinal and supraspinal neurons within the transplant and the host cord caudal to the lesion and the extent of recovery of locomotion, including weight-supported plantar stepping on both treadmill and over-ground tasks (stair climbing), as well as skilled and unskilled forelimb function were dramatically increased when transplants and neurotrophins were administered 2-4 weeks after a spinal cord transection rather than immediately after injury (Iarikov et al. 2007 ). These findings suggest that the opportunity for intervention after spinal cord injury may be greater than originally envisioned and that CNS neurons with long-standing injuries can reinitiate growth, leading to improvement in motor function.
Additional strategies also enhance the effects of fetal spinal cord tissue transplants. Acute transplants after transection combined with delayed hindlimb cycling exercise restored muscle mass and motoneuron properties (Houle et al. 1999) . Acute transplants after hemisection combined with delayed systemic administration of the phosphodiesterase 4 inhibitor rolipram increased axonal regrowth within them and improved forelimb function (Nikulina et al. 2004 ).
Clinically, pieces of human fetal spinal cord have been transplanted into a small number of patients with syringomyelia, that is, expanding cystic lesions of the spinal cord Reier 2004 ). The surgical procedure was found to be feasible and safe which is particularly important as the subjects had chronic SCIs. Cysts were filled and there were no negative changes of neurophysiological measures . Relatively modest sensory improvement and pain reduction were reported. However, there was a transient decrease of spasticity as well as gait and proprioception deterioration in one subject. Graft survival was equivocal so it is unclear whether transplant rejection and/or cyst expansion occurred. Since detethering, cyst drainage, and immunosuppression were performed, their roles in the effects cannot be discounted. To our knowledge, there are no articles reporting the results of basic experiments using fetal tissue transplants to improve respiration. Therefore, these need to be performed before clinical trials can be considered.
Cell transplantation
Many kinds of cells are considered candidates for transplantation therapy (Table 1) . In this section, focus is placed on those cell types with promise to be translated into clinical studies.
Schwann cells
Schwann cells were originally described by and named after the German anatomist Theodore Schwann (1810-1882). They are a major cellular component of the peripheral nerve and play a key role in its regeneration (Oudega et al. 2006) . For example, following peripheral nerve injury, axons in the distal nerve stump undergo Wallerian degeneration. Schwann cells dedifferentiate into non-myelinating Schwann cells, proliferate extensively and phagocytose myelin debris actively. The proliferating Schwann cells are located within basal lamina tubes and form column-like structures known as bands of Bünger. The Schwann cells also start to increase expression of various growth factors thereby creating a growth permissive environment for axonal regeneration. It was the discovery of this key role of Schwann cells in peripheral nerve repair, the observation of CNS axonal regeneration into transplanted peripheral nerves, and the findings of Schwann cells in the damaged CNS that generated interest in them as a potential candidate for cellular approaches to repair the injured CNS.
Schwann cells have several unique features making them one of the best cell types for therapy. First, they express a variety of factors that support the growth of central axons. Among them are members of the neurotrophin family including nerve growth factor (NGF), BDNF, and NT-3, as well as ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), and FGF. Second, Schwann cells express surface molecules such as L1/Ng-cell adhesion molecules (CAM) and N-CAM, both of which have been demonstrated to support axon growth through contact guidance. Finally, Schwann cells produce axon growthpromoting substrates such as laminin, fibronectin, and collagen [For review, see (Oudega et al. 2006) ].
One principal advantage of Schwann cells over other cell types for transplantation into the injured CNS is that Schwann cells are able to myelinate both regenerating and intact central axons. This was first shown by Gilmore (1971) . Many other cell types promote axonal regeneration, but do not form myelin sheaths around the new axon sprouts. Schwann cells do so and thus facilitate signal conduction in the regenerated axons. If myelination would not occur after regeneration and formation of synaptic contacts, the functioning of the new circuits would be significantly impaired similar to what is seen in multiple sclerosis.
To employ Schwann cells for transplantation into the injured CNS, obtaining large numbers is necessary to fill up large and numerous cystic cavities that develop. Fortunately, several methods have been described to harvest purified populations of numerous Schwann cells (Wood 1976; Brockes et al. 1979) . To obtain these Schwann cells, several mitogens have been used, include bovine pituitary extract containing glial growth factor (GGF). Raising the intracellular level of cAMP with dibutyryl cAMP and cholera toxin (Raff et al. 1978) as well as forskolin, a potent adenylate cyclase activator (Evans et al. 1985) , has been seen to be effective. In 1991, Morrissey and colleagues (Morrissey et al. 1991 ) developed a method to isolate and obtain large numbers of essentially pure populations of Schwann cells from the adult rat peripheral nerve. The difference between this and previously described approaches was that small nerve explants were allowed to undergo axonal and myelin breakdown rather than enzymatic dissociation of the nerve immediately after dissection. By combining this approach with the use of the mitogenic combination of GGF and forskolin for up to 10 weeks in vitro, several millions of Schwann cells at a purity of 98% could be obtained. Using this purification technique, Morrissey and co-workers were also able to obtain Schwann cell cultures from human phrenic nerve. Casella and colleagues (Casella et al. 1996) further improved the method of Morrissey by using the mitogenic combination of heregulin and forskolin for 2 weeks prior to dissociation of the human nerve explants. Importantly, the cultured Schwann cells were shown to retain their ability to myelinate and promote axonal regeneration. This opened a new avenue for preparing large quantities of autologous Schwann cell transplants for human application. One could envision that for a spinal cord injured patient, a piece of peripheral nerve can be taken from them and prepared to isolate and propagate a large number of Schwann cells for transplantation.
The efficacy of Schwann cells in promoting axonal regeneration and myelination in the injured adult mammalian PNS and CNS has been extensively studied in a variety of experimental models (Oudega et al. 2006; Bunge 2008) . Schwann cells transplanted into injured peripheral nerve, optic nerve, septo-hippocampal system, diencephalon, and spinal cord survived, promoted axonal regeneration, and ensheathed or myelinated the regenerated axons (see review by (Oudega et al. 2006; Bunge 2008) ). In cases where axons in the spinal cord were demyelinated but not severed, remyelination by grafted Schwann cells re-established normal conduction velocity across the lesion and thus achieved functional repair. Moreover, Schwann cells mixed with Matrigel, a commercial preparation of basement membrane components, when seeded into semipermeable polyacrylonitrile/polyvinylchoride (PAN/PVC) polymer tubes then grafted between stumps of the completely transected or hemisected (Xu et al. 1999 ) adult rat thoracic spinal cord have been shown to promote propriospinal and supraspinal axonal growth across the gap and myelination. The cord stumps were bridged by a tissue cable that contained Schwann cells and axons were at different stages of myelination or ensheathment by Schwann cells (Xu et al. 1995a; Xu et al. 1995b; Xu et al. 1997) (Fig. 1) . The absence of Schwann cells in control grafts resulted in scarce axonal growth.
Although grafting Schwann cells into the lesion site has been shown to promote regeneration and myelination, the axons do not regenerate beyond the transplantation site. To achieve further axonal advancement beyond the inhibitory glial scar surrounding the injury, additional approaches such as increasing the intrinsic capacity of axons to regenerate and/or removal of the inhibitory molecules associated with reactive astrocytes and/or CNS myelin should be incorporated. Clearly, combinatorial interventions involving Schwann cells and other effective repair strategies, discussed below, are capable of achieving greater axonal regenerative responses and biologically significant functional recoveries. Moreover, a report one year after autologous Schwann cell transplantation into chronically spinal cord injured persons indicates that it is safe and feasible (Saberi et al. 2008) . Continued preclinical development of these approaches to neural repair may ultimately generate strategies that could be tested in human CNS injuries such as those being proposed at The Miami Project to Cure Paralysis of the University of Miami School of Medicine.
Olfactory ensheathing glia
Over the last decade, experiments from different laboratories have demonstrated compelling evidence that olfactory ensheathing glia (OEG) too are a promising cell source for CNS repair. The OEG are also named olfactory glial cells or olfactory ensheathing cells. They ensheath axons of olfactory receptor neurons which leave the olfactory mucosa, enter the olfactory bulb where they comprise the olfactory nerve fiber layer, and finally synapse with second order neurons (mitral cells) in the glomerular layer (Franklin et al. 1997b ).
The OEG have traditionally been regarded as straddling the boundary between PNS and CNS glia since they bear similarities to both Schwann cells and astrocytes. Their similarities to Schwann cells, particularly non-myelinating Schwann cells, include the expression of many shared antigenic markers , ensheathment of axons, and supporting axonal growth in the adult (Doucette 1993) . OEG resemble astrocytes in that they express the astrocyte-specific isoform of glial fibrillary acidid protein (GFAP) and form the cellular boundary of the olfactory bulb, similar to the astrocytic glia limitans (Franklin et al. 1997b ).
OEG have been implicated in the regeneration beyond an injury and/or scar into host nervous tissue of injured axons in discrete and complete SCI models (Li et al. 1998; Ramon-Cueto et al. 1998; Ramon-Cueto et al. 2000) . For example, long distance axonal regeneration of multiple supraspinal pathways, along with recovery of sensory and motor functions, and attenuation of muscle phenotypic deterioration was achieved following complete thoracic spinal cord transection and implantation of OEG on either side and into the transection site (Ramon-Cueto et al. 2000; Negredo et al. 2008) . Improved function also has been observed after discrete, incomplete, and complete SCI when chronic transplants (Lopez-Vales et al. 2007 ), OEG overxpressing BDNF (Ruitenberg et al. 2003) , and GDNF (Cao et al. 2004 ), xenografts of primate OEG (Guest et al. 2008) , and step training (Kubasak et al. 2008) were used. However, forelimb function was impaired when OEG transplantation was combined with BDNF delivery to the red nucleus (Bretzner et al. 2008) . Importantly, phrenic and diaphragmatic activities recovered (Polentes et al. 2004 ) and breathing was restored (Li et al. 2003) when OEG were transplanted after cervical SCI ( Table 2 ).
The mechanisms underlying this OEG-induced growth response are still in debate. When transplanted into the injured spinal cord, they migrated considerably in the white matter tracts, gray matter, and glial scar (Ramon-Cueto et al. 1998 ). It may be that the OEG migrate with the growing axons, thereby preventing the axon from recognizing the non-permissive milieu. Another option is that OEG transplants do not result in adverse reactions of the nervous tissue to axonal extension. The latter option is supported by the finding that transplanting OEG into adult white matter resulted in a decreased astrocytic response and decreased expression of the growth-inhibitory molecules, chondroitin sulfate proteoglycans (CSPGs) (Takami et al. 2002) .
One limitation of using of OEG is that these cells normally ensheathe but do not myelinate axons. Although previous experiments showed myelin-forming capabilities of transplanted OEGs on demyelinated or regenerated axons, the possibility that the myelin formed by endogenously-(or exogenously-) derived Schwann cells rather than OEG remains to be excluded. It was demonstrated that transplants of purified populations of OEG resulted in less extensive remyelination than those of unpurified preparations (Lakatos et al. 2003) . Since OEG and Schwann cells share many growth-promoting properties but that they also exhibit different characteristics, these two cell types may be grafted together to achieve a complementary goal. For example, a combined strategy involving Schwann cell transplantation into the lesion cavity and OEG transplantation near the graft-host interfaces may utilize both growth-promoting and myelin-forming properties of Schwann cells and interface-modification properties of OEG, therefore, promoting continuous axonal regeneration through and beyond the lesion site. This strategy has been successfully used in a study when a spinal cord gap was bridged by a Schwann cell-seeded guidance channel and the adjacent cord stumps received injections of OEG (Ramon-Cueto et al. 1998) . In this study, the combined transplantation resulted in regeneration of both proprio-and supraspinal axons across the lesion gap which was not achieved when a Schwann cell-seeded guidance channel alone was used. Combining this approach with Schwann cell transplantation and chondroitinase ABC spinal cord delivery was reported to improve locomotion and to prevent bladder dysfunction (Fouad et al. 2009 ). Locomotion also was improved when transplants of OEG and Schwann cells were combined with methylprednisolone and interleukin-10 ( Pearse et al. 2004) , and enriched housing (Moon et al. 2006 ).
Human adult olfactory neural progenitors too have been observed to promote recovery of adult rat forelimb function after dorsolateral funiculotomy SCI (Xiao et al. 2005) . Clinical studies have reported that OEG transplantation is feasible and safe (Mackay-Sim et al. 2008) and that improved motor and sensory function occurred ) (Lima et al. 2006) . A number of biomedical, and ethical issues were raised about some of the fetal cell transplants performed that need to be critically considered when evaluating the results and for all future cell and tissue transplant clinical studies (Dobkin et al. 2006 ). These include preclinical results, randomized trials with placebo control interventions, SCI recipient selection requirements, blood typing and tissue matching between donors and recipients, type of cell transplanted, site of transplantation, use of methylprednisolone, medical complications, comprehensive plan for objective pre-and post-surgery assessments, and functional effectiveness.
Stimulated macrophages
Post-injury recovery in most tissues requires an effective dialog with macrophages. However, in the adult mammalian CNS this may be restricted possibly due to its immune-privileged status. Initial laboratory comparisons of inflammatory responses associated with PNS injury versus CNS trauma suggested that the lack of regeneration in the spinal cord and brain could be attributed to a compromised recruitment of macrophages (Hirschberg et al. 1995) . Subsequent experiments, first in an optic nerve injury model, showed that regeneration could be elicited by augmenting the endogenous inflammatory response with grafts of activated macrophages that had been pre-incubated in the presence of PN tissue (Lazarov-Spiegler et al. 1996) . Implantation of stimulated macrophages into transected rat spinal cord promoted tissue repair and partial recovery of motor function, manifested behaviorally and electrophysiologically (Rapalino et al. 1998) . Anatomically, labeled axons were found to cross the transected site and descend distally. Re-transection of the recovered spinal cord above the primary injury site led to loss of recovery.
Although some positive results have been reported and the strategy was studied clinically by Proneuron in a Phase I safety study (Knoller et al. 2005 ) that led to a suspended Phase II study, controversy exists regarding the use of activated macrophages to boost post-injury inflammatory responses for axonal regeneration in the injured spinal cord (Reier 2004 ).
Activation of intrinsic macrophages with microinjections of zymosan into a spinal contusion site resulted in deleterious effects on hindlimb functional recovery and tissue survival (Popovich et al. 2002) . Furthermore, depletion of peripheral macrophages, during a time when inflammation has been shown to be maximal after spinal contusion injury in rats, led to significantly better hindlimb usage during overground locomotion, more extensive white matter sparing, and decreased tissue cavitation (Popovich et al. 1999) . Thus, more work needs to be done to determine the beneficial or detrimental roles that the reactive macrophages may play in response to CNS injuries as well as the underlying mechanisms to better appreciate this therapy.
Neural stem cells and embryonic stem cells
Multipotent neural stem cells (NSCs) are found in mammals throughout their lifetime and recruiting them may be therapeutic. Neural stem cells are defined by their ability to self-renew and retain the potential to differentiate into both neurons and glia (Gage 2000) . Cells with these properties were first isolated from the forebrains of adult and embryonic mice. These NSCs proliferate as neurospheres in culture in response to either epidermal growth factor (EGF) or fibroblast growth factor-2 (FGF-2) combined with heparan sulphate (HS) (Fig. 2) . In addition to the forebrain, the spinal cord is another enriched source of NSCs in the CNS . Neural stem cells can be repetitively passaged and maintained for a long time in vitro. They express the intermediate filament nestin (abbreviated for neuroepithelial stem cell protein) but not markers for differentiated neuronal or glial cell types. In addition, NSCs retain their multipotentiality and can be induced to produce enriched populations of glial or neuronal progenitors using defined extrinsic factors in vitro. Furthermore, these cells may differentiate into neural cells with appropriate phenotype(s) after transplantation and possibly reestablish connectivity within a specific CNS region. These unique properties of NSCs relative to other neural cell types potentially allow for the design of cellular transplants that can fulfill specific needs in the repair of the damaged CNS, making NSCs a promising candidate for neural transplantation in traumatic spinal cord and brain injuries and several other neurological diseases.
Several transplantation strategies utilizing neural stem or progenitor cells have been evaluated. Using an ex vivo gene transfer approach, Liu and colleagues ) grafted neural stem cells expressing NT-3 into the normal spinal cord at the T8 level. These cells survived, integrated into the host spinal cord, and differentiated into neurons, astrocytes, and oligodendrocytes. The cells also migrated as far as one centimeter from the site of grafting, indicating that spinal cord repair may extend rostrally and caudally. Transplants of embryonic day (E)14 spinal cord NSCs into a partial hemisection cavity of the spinal cord, combined with exogenous BDNF administration, resulted in the differentiation of these cells into neurons, astrocytes, and oligodendrocytes, however, most of the grafted cells appeared undifferentiated (Chow et al. 2000) . Additionally, NSCs isolated from the E14 rat cerebral cortex or adult rat subventricular zone when transplanted into normal and contused adult rat spinal cords either remained nestin-positive or differentiated along the glial lineage (Cao et al. 2001) .
Remaining undifferentiated or differentiating into predominantly glia is a potential problem for the direct transplantation of NSCs into intact or injured adult CNS regions. The differentiation fate of neural stem cells may be strongly influenced by specific cues from the local environment of engraftment (Onifer et al. 1993) . It is only when NSCs are transplanted into the developing brain or areas in the adult brain undergoing active neurogenesis that significant numbers differentiate into region-appropriate neurons (Flax et al. 1998 ). For example, adult spinal cord-derived NSCs when transplanted into the adult rat spinal cord (nonneurogenic region) differentiated into glial cells; however, when they were transplanted into the granular layer of hippocampus (neurogenic region) they differentiated into cells characteristic of this region (Shihabuddin et al. 2000) . Engraftment of these cells into other hippocampal regions resulted in the differentiation of cells with astroglial and oligodendroglial phenotypes. These data indicate that NSCs obtained from a non-neurogenic region (such as the spinal cord) are not lineage-restricted to their developmental origin but can generate regionspecific neurons in vivo when exposed to the appropriate environmental cues (Shihabuddin et al. 2000) . Prior growth factor induction of stem cell differentiation along neuronal or glial cell pathways may be necessary for successful repair to occur. When neuronal-restricted precursors (NRPs), a NSC-derived neuronal lineage, were grafted into the normal adult rat dentate gyrus, they showed mature neuronal morphology with robust processes. Some grafted cells showed morphological characteristics of pyramidal neurons in the CA1 region. These cells expressed the mature neuronal marker NeuN and calbindin, a protein that was not expressed by NRPs in vitro. When NRPs were transplanted into the normal rat spinal cord, they differentiated into neurons; some of them expressed γ-amino butyric acid, glutamate, and choline acetyltransferase.
An additional source of NSCs is from blastocyst-derived cells, which are expanded as totipotent embryonic stem (ES) cells (Svendsen et al. 1999) . Induction of ES cells into committed precursors can yield purified populations of NSCs, precursors, or differentiated neural cell types (Svendsen et al. 1999) . The resulting stem cells can be expanded in culture as neurospheres which may then be used for transplantation. Grafting of neural differentiated mouse ES cells into a rat thoracic spinal cord contusive injury resulted in the survival, migration, differentiation into astrocytes, oligodendrocytes and neurons, and improved locomotor function (McDonald et al. 1999 ).
An advancement of the NSC research is the development of methods in isolating human NSCs for clinical applications. Human NSCs have been isolated from embryonic forebrain by growth factor expansion in response to a defined medium containing both FGF-2 and EGF. In contrast to rodent neurospheres, a synergistic combination of these growth factors is required for survival and proliferation of human NSCs (Vescovi et al. 1999 ). In addition, leukemia inhibitory factor and CNTF, both members of the IL-6 cytokine family that are not required for rodent stem cell survival and proliferation, are capable of enhancing the proliferation and expansion of human stem cells as compared to neurospheres cultured only in EGF and FGF-2 (Carpenter et al. 1999) . Human NSCs isolated from first-trimester embryonic forebrain have been shown to remain multipotent for at least one year in vitro (Carpenter et al. 1999 ).
Oligodendrocyte progenitor cells
A unique cell type that shows great promise in CNS repair is the oligodendrocyte progenitor cell (OPC). These cells likely represent the progenitor cells of mature oligodendrocytes that produce myelin in the CNS. Oligodendrocytes isolated from the rat optic nerve express A2B5 and platelet-derived growth factor (PDGF) receptor alpha (PDGFR-α) in vitro and can differentiate into oligodendroglia in serum-free medium or type-2 astroglia in serumcontaining medium (Raff et al. 1983) . Using this culture system, a number of growth factors or cytokines have been found to regulate the survival, proliferation, migration, differentiation, and myelination of the oligodendrocyte lineage (Barres et al. 1992) . For example, a combination of PDGF and basic fibroblast growth factor (bFGF, FGF-2) induced a sustained self-renewal of the OPCs and prohibited them from differentiating into oligodendroglia (McKinnon et al. 1990 ). OPCs can also be differentially induced from neuroepithelial cells (NPCs) ). The generation of OPCs from multipotent NPCs in vivo is thought to be induced by factors produced by the notochord and/or floor plate of the neural tube. When adult mouse brain-derived NPCs were transplanted with delay into the compression-injured adult rat spinal cord, OPCs, oligodendrocytes, and myelin were formed and function improved (Karimi-Abdolrezaee et al. 2006 ). PDGF, FGF-2, epidermal growth factor were delivered at the transplantation site and both cyclosporine A and minocycline were administered, however, these did not alter spontaneous functional recovery.
The promise of using OPCs for cell therapy primarily lies in their ability to form central myelin on demyelinated axons. Demyelination of intact axons contributes to the physiological and functional deficits after many CNS disorders and trauma. For example, in both human (Bunge et al. 1993) and contusive animal models of SCI (Blight 1985) , demyelination due to oligodendrocyte cell death occurs. Apoptosis plays a major role in oligodendrocyte cell death especially in white matter tracts remote to the SCI site (Crowe et al. 1997; Liu et al. 1997) . Remyelination of demyelinated intact axons, and regenerated axons as mentioned above, thus represents an important repair strategy to facilitate functional recovery. Moreover, the survival of oligodendrocytes and axons may be interwoven.
It was demonstrated that OPCs (A2B5+/O4−) produced more myelin over a wider area than did the more mature stages of the lineage (O4+/GalC− and GalC+ cells) when transplanted in neonatal shiverer mice (Warrington et al. 1993) . As a consequence of this and other studies (Groves et al. 1993) , the A2B5+ OPCs became the focus for a number of subsequent transplantation studies. When they were transplanted into x-irradiation + ethidium bromide (X-EB) lesions, as many as 90% of the available axons had been reinvested with central myelin sheaths at 21 d post-transplantation, indicating that transplanted OPCs were able to differentiate into myelinating oligodendrocytes within the lesion environment (Groves et al. 1993) . The transplant origin of the myelinating cells was confirmed by labeling them with the marker gene LacZ (Franklin et al. 1997a) . A similar degree of remyelination of X-EB lesions can be achieved using an oligodendrocyte progenitor cell line -the CG4 cell line (Franklin et al. 1995) .
Demyelination in the ventral and lateral spinal white matter results in locomotor and electrophysiological deficits that also can be seen following a contusive SCI involving this region (Cao et al. 2005b) . When OPCs (also called glial restricted precursors or GRPs), infected with retroviruses expressing multi-neurotrophin D15A (with both BDNF and NT-3 activities), were transplanted into the contused adult thoracic spinal cord at 9 days post-injury, they differentiated into mature oligodendrocytes at 6 weeks after transplantation (Cao et al. 2005a ). These grafted D15A-GRPs formed typical central myelin around axons in the ventrolateral funiculus (VLF) of the spinal cord. Importantly, they resulted in recovery of transcranial magnetic motor-evoked potential responses, indicating that conduction through the demyelinated VLF axons was restored. Recovery of hindlimb locomotor function was also significantly enhanced in the combined D15A-GRP group indicating this approach may be a useful therapeutic strategy to repair the injured spinal cord.
In a recent study, OPCs were induced to differentiate from human ES cells (Keirstead et al. 2005) . When these human-derived OPCs were transplanted into adult rat contusive spinal cord injuries, they survived, redistributed over short distances, and differentiated into oligodendrocytes. Furthermore, animals that received OPCs at 7 days post-injury exhibited enhanced remyelination and substantially improved locomotor ability. These studies demonstrated the ability of human OPCs, pre-differentiated from the human ES cells, to myelinate injured CNS axons and their therapeutic potential in the repair of CNS injuries. The United States Food and Drug Administration recently approved a safety clinical trial by Geron Corporation of OPCs derived from human ES cells for transplantation into spinal cord injured persons.
Whether OPCs could promote regeneration of injured axons remains to be elucidated. The observation that OPCs expressing neither extracellular domain of Nogo-A nor MAG were significantly more permissive than mature oligodendrocytes expressing both indicates that transplantation of OPCs may represent a feasible strategy to foster CNS axonal regeneration (Ma et al. 2009 ).
Bone marrow stromal cells
Bone marrow stromal cells (MSCs) are particularly attractive for CNS repair because they are easy to isolate and expand from patients without serious ethical and technical problems. MSCs initially attracted attention because of their stem cell-like attributes and pluripotency (Pittenger et al. 1999) . Several laboratories have demonstrated that these cells have the ability to give rise to neurons and glia. These findings, however, have not been corroborated. Moreover, they have been subject to challenges based on issues pertaining to cell fusion and trans-differentiation (Terada et al. 2002; Camargo et al. 2004) as well as to the absence of distinct neuronal morphological features and properties despite their expression of some neuronal markers. Recent observations (Cogle et al. 2004) showing that human hemopoietic cells can transdifferentiate into neurons, astrocytes, and microglia in a long-term setting without fusing have revived the trans-differentiation potential. Whether this applies to MSCs is unclear.
Autologous MSCs can be delivered via intramedullary or intravenous routes. After being transplanted into CNS lesions, they can migrate into the surrounding tissue and differentiate into neurons or astrocytes, enhance tissue repair of the lesion, stimulate regrowth of axons across the lesion site, and promote functional recovery (Zurita et al. 2004 ). When combined with pegylated BDNF delivery (Ankeny et al. 2001) or BDNF gene-transfer (Lu et al. 2002) , MSCs improved axonal regeneration and/or recovery of function after SCI. In related studies, Kocsis and his associates saw increased myelination after the infusion of MSCs either intravenously (Akiyama et al. 2002) or into the spinal cords (Sasaki et al. 2001) of rats damaged by x-ray irradiation. Although MSCs are a promising cell type for cell therapy, the potential mechanisms by which they may be acting remain unclear at the existing level of analysis, although neurotrophic and axonal elongation facilitating actions have been proposed. Also, the functional outcomes reported must be cautiously interpreted because many are primarily based on one evaluation protocol without other correlative behavioral/electrophysiological approaches (Reier 2004) . The development of methods for efficient and specific induction of functional post-mitotic neuronal cells from both rat and human MSCs and transplantation of these cells into animal models of CNS trauma and disorders should provide a solid background for the possibility of their clinical application. Autologous MSC transplantation acutely and sub-chronically after complete SCI when combined with granulocyte macrophage-colony stimulating factor delivery was found to be safe and led to modest functional improvements in a Phase I/II open-label and non-randomized study with a control group (Yoon et al. 2007 ).
Combining transplantation-mediated therapy with other repair strategies
Traumatic injury to the CNS initially as well as inevitably disrupts axonal continuity which in turn leads to functional deficits. The extent of the deficits is determined by the severity of the primary lesion, its location, and many complex secondary injury processes. Unfortunately, most axons in the adult mammalian CNS have little intrinsic ability to regenerate. To date, it is clear from experimental and clinical evidence that no single factor accounts for the lack of axonal regeneration after CNS injuries. Failure of successful axon regeneration is particularly attributed to the diminished intrinsic capacity of neurons to regenerate, the presence of physical and chemical barriers associated with the glial scar, and the existence of myelin-associated growth inhibitors in the injured CNS. Therefore, successful functional recovery in patients suffering from CNS injuries will not simply rely on a single therapeutic strategy. There unlikely will be a 'silver bullet'. The repair strategies discussed above may one day be developed to individually bring about certain degrees of anatomical regeneration and functional improvement. However, the extent of the repair response will not be enough to guarantee optimal biologically significant recovery of neurological function. These individual strategies, however, can be combined to achieve a greater or maximal regeneration and functional recovery. Table 3 summarizes, to our knowledge, the most promising repair strategies that may ultimately be combined. Each of these strategies addresses a specific problem associated with axonal injury, regeneration, and target reinnervation. The effects of combinations that have been evaluated experimentally have been discussed throughout this chapter.
Summary and perspectives
In spite of the tremendous efforts of various prevention programs throughout the world, neurotrauma and neurodegenerative diseases occur. To promote CNS axons to regenerate, one critical repair strategy is to stimulate the neurons' intrinsic capacity to do so. Another effective approach is to overcome the inhibition associated with CNS myelin and/or glial scar. Since damaged axons need a physically growth-permissive terrain to regenerate across the injury site, usually characterized by large cavities, transplantation of tissues or cells, combined with permissive trophic factors and cell adhesion molecules, is essential for creating such a terrain. It now is the consensus that successful functional recovery in patients suffering from CNS injuries will not simply rely on a single therapeutic strategy. Future repair strategies will likely include combination of multiple approaches such as the ones shown in Figure 3 . In addition, they may also be combined with neural protection and rehabilitation/physical therapy to maximize neural regeneration, plasticity and functional recovery after CNS injury.
Significant progress has been made over the last two decades about injured CNS axon regeneration. It is no longer a matter of whether regeneration can occur. The experimental findings have already led to previous clinical trials and new ones that are underway and being planned. Very importantly, future trials will need to adhere recommendations for their scientific and ethical conduct (Hawryluk et al. 2008 ). The present and future challenges are to determine in the laboratory how to optimize injured CNS axon regeneration and target site reinnervation so as to maximize respiration and other functional recovery for both chronically and those to be injured persons. Combinatorial strategies for regeneration of the injured CNS. Both centrally-(such as NSCs or OPCs) or peripherally-(such as Schwann cells) derived cells can be used for transplantation into the CNS. These cells can be combined with other strategies such as boosting the intrinsic regenerative capacity of injured neurons, decomposing the glial scar at the graft-host interfaces, generating growth promoting pathways in the distal host spinal cord, and enhancing synaptic reconnection between regenerating axons and their targets to achieve better anatomical regeneration and functional recovery after various CNS injuries. (Adapted from He and Xu, Chapter 29, Regeneration and Transplantation, In Neuroscience (Han JS and Poo M-M, Eds) (In Press).
